<DOC>
	<DOC>NCT01833741</DOC>
	<brief_summary>This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.</brief_summary>
	<brief_title>A Study of LUMIGAN® RC in the Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Elevated IOP due to either primary openangle glaucoma or ocular hypertension Determined by the treating physician to require treatment with LUMIGAN® RC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>